Parameters of rotational thromboelastometry in patients with moderate and severe psoriasis: a pilot study
- PMID: 40593457
- PMCID: PMC12611982
- DOI: 10.1007/s11239-025-03140-z
Parameters of rotational thromboelastometry in patients with moderate and severe psoriasis: a pilot study
Abstract
Introduction: Several studies have repeatedly described an increased risk of thrombotic complications in patients with severe psoriasis. Rotational thromboelastometry (ROTEM) is a viscoelastic hemostatic test that allows sophisticated in-vivo evaluation of hemostasis in whole blood samples. This study aimed to assess hemostatic changes in psoriatic patients using ROTEM.
Methods: This pilot, observational, prospective study included 62 patients with moderate and severe psoriasis and a control group of 61 healthy blood donors. Blood samples were tested using the ROTEM Gamma analyser (Pentapharm GmbH, Munich, Germany) with INTEM, EXTEM, and FIBTEM reagents. We measured clotting time (CT), clot formation time (CFT), maximum clot firmness (MCF), amplitude at 10 and 20 min post-CT (A10, A20) and alpha angle.
Results: The psoriatic patient group consisted of 31 men and 31 women, while the control group included 34 men and 27 women. Comparing patients with psoriasis and the control group, we identified statistically significant differences in the parameters: CT-EXTEM (74.8±1.4s vs. 69.7±1.4s; p < 0.05), MCF-EXTEM, A10-EXTEM, A20-EXTEM, CFT-INTEM, A10-INTEM, A20-INTEM, alfa-INTEM, CT-FIBTEM (67.3±1.2s vs. 62.8±1.2s; p < 0.05), CFT-FIBTEM and alfa-FIBTEM.
Conclusions: In this pilot study, compared to the controls, patients with moderate to severe psoriasis exhibited a shift in hemostasis towards a procoagulant state in ROTEM analysis.
Keywords: Hypercoagulation; Psoriasis; Rotational thromboelastometry; Venous thromboembolism.
Conflict of interest statement
Declarations. Ethics approval and consent to participate: This research was performed according to ethical standards and was reviewed and approved by the local ethical review board (Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, decision protocol No. EK 68/2020). The patients agreed to participate in this study and signed informed consent for study participation. Competing interests: The authors declare no competing interests.
References
-
- Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y, Troxel AB, Hennessy S, Kimmel SE, Margolis DJ, Choi H, Mehta NN, Gelfand JM (2015) Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: A Population-Based cohort study. Ann Rheum Dis 74(2):326–332. 10.1136/annrheumdis-2014-205675 - DOI - PMC - PubMed
-
- Ahlehoff O, Gislason GH, Lindhardsen J, Charlot MG, Jørgensen CH, Olesen JB, Bretler D-M, Skov L, Torp-Pedersen C, Hansen PR (2011) Psoriasis carries an increased risk of venous thromboembolism: A Danish nationwide cohort study. PLoS ONE 6(3):e18125. 10.1371/journal.pone.0018125 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
